Results 51 to 60 of about 418,673 (161)
The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2
Качественная клиническая практика, 2018 Modelling has been performed for evaluation of economic perspectives of new insulin glargine 300 IU/ml usage for diabetes mellitus type 2 (DM2) control based on literature analysis of non-direct comparison with insulin detemir.
D. Yu. Belousov, E. V. Afanasyeva
doaj
Internal Medicine Journal, EarlyView.Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos +5 more
wiley +1 more source
Estimation of insulin sensitivity from continuous glucose monitoring and insulin pump data in type 1 diabetes [PDF]
, 2012 Diabetes mellitus is a disease characterized by chronic hyperglycemia either due to a lack of secretion of the hormone insulin (Type 1 Diabetes Mellitus, T1DM) or due to impaired action of this hormone (Type 2 Diabetes Mellitus, T2DM).
Ronca, Gabriele
core
Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats
Endocrine Connections, 2018 It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer ...
Yusaku Mori +8 more
doaj +1 more source
BMC Endocrine Disorders, 2021 Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials.
Bin Sun +11 more
doaj +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang +6 more
wiley +1 more source
PLoS ONE, 2014 AimsTo compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs.MethodsPeople with inadequately controlled ...
Cheol-Young Park +6 more
doaj +1 more source
Long‐term survival after surgical removal of an intermediate grade pancreatic carcinoma in a cat
Veterinary Record Case Reports, Volume 14, Issue 4, November 2026.Abstract An 11‐year‐old male neutered domestic shorthair cat presented with a history of acute diarrhoea, decreased appetite, and a palpable abdominal mass. Following clinical staging and histopathological examination after partial pancreatectomy, the cat was diagnosed with a completely excised intermediate grade pancreatic carcinoma without evidence ...
Abel Verbrugghe +4 more
wiley +1 more source
Diabetic Medicine, Volume 43, Issue 11, November 2026.Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney +14 more
wiley +1 more source
Insulin glargine in enteric tube feeding.
, 2007 Diabetes Res Clin Pract. 2007 Nov;78(2):298-9. Epub 2007 May 3. Insulin glargine in enteric tube feeding. Marchetti G, Tesauro M, Di Daniele N, Bollea MR, Lauro R, Bertoli A.
Bollea, MR +10 more
core +1 more source